|
|
||||||||

,*
| ABSTRACT |
|
|
|---|
| INTRODUCTION |
|
|
|---|
In MayJune 2003, human infections with monkeypox virus were reported in the United States following importation of virus infected animals that had been collected in the wild from the west African nation of Ghana.11 This event represents the sole instance whereby monkeypox virus exported from virus-endemic regions has resulted in human infections. The manifestations of human illness seen during the U.S. outbreak were relatively mild (with exceptions1214), although the individuals affected were on average older than those generally observed with severe disease in African outbreaks. Notably, no human-to-human virus transmission was reported during the 2003 US outbreak, and there were no human deaths11 (Cono J, unpublished data).
In pronounced contrast to this, a nearly simultaneous focus of human monkeypox was identified in the town of Impfondo in the remote heavily forested district of Likouala in the Republic of Congo. This outbreak likely began in April 2003, and ended with recovery of the last case in mid-July. Most of the reported infections occurred in children < 12 years of age, many of whom were hospitalized with serious illnesses. Human-to-human transmission was a prominent feature of this outbreak, with seven generations (six sequential passages) of serial transmission hypothesized to have occurred.
| MATERIALS AND METHODS |
|
|
|---|
|
Epidemiologic and clinical information. Clinical and epidemiologic information pertaining to cases was collected using patient and family interviews, physician notes, and hospital records as data sources.
Laboratory analysis of clinical specimens. Molecular, virologic, and serologic assays were used for diagnosis of monkeypox and/or orthopox virus infection in symptomatic individuals. Polymerase chain reaction (PCR)based molecular assays were performed using DNA prepared from lesions, swabs, smears, and EDTA-whole blood specimens; in some cases whole, unpreserved blood was used if no other samples were available. Specimens positive for monkeypox were those that yielded positive results in at least two independent PCR tests (targeting different loci), including one that discriminates monkeypox-specific DNA signatures from those of other orthopox viruses. Assays designed to detect generic-level and species-specific DNA signatures, as well as virus culture procedures, have been described elsewhere.13,15,16
Serologic testing alone was used to define disease status for individuals who had a recent compatible illness, but no active lesions at the time of specimen collection. Enzyme-linked immunosorbent assays were used for detection of orthopox-specific IgG or IgM antibodies from patient sera 14. The presence of elevated levels of orthopox reactive IgG antibodies in sera can indicate either monkeypox infection, or a previous vaccination against smallpox. The presence of elevated IgM titers between, at minimum, days 756 post-rash onset in persons with compatible clinical and epidemiologic characteristics is considered an indication of probable case status (Appendix 1
).
|
| RESULTS |
|
|
|---|
|
|
Case 3, the infant son of case 2, stayed with his mother throughout her hospitalization. Both received nursing care from the infants grandmother, case 6 (suspect). Twenty-two days into the hospitalization of case 3, another sick child, case 5, was moved into the same room; two weeks later, case 6 developed fever, headache, and malaise. Case 6 never developed a rash, and laboratory testing for evidence of monkey-pox infection, or recent orthopoxvirus exposure, was inconclusive. Case 6 was observed to have a smallpox vaccination scar.
Two patients were initially admitted to the hospital with presumptive diagnoses of malaria (5b and 6a). Case 5b may have been incubating monkeypox when hospitalized for suspected malaria. Upon treatment, his first fever abated only to recrudesce on day 7 post-admission. He developed vesiculo-pustular lesions on the palms of his hands, soles of his feet, and trunk three days later. Case 6a was treated and discharged for malaria prior to being readmitted nine days later with the above characteristic signs of monkeypox. He reported no other exposures to monkeypox and is likely to have acquired his infection during his hospitalization for malaria.
Active surveillance among exposed hospital staff was not formally pursued. However, none of the adult health care workers at the Government Hospital in Impfondo reported experiencing symptoms of febrile illness either during, or up to three weeks after the time that monkeypox patients were hospitalized. Household census information was insufficient to allow for reliable calculation of secondary attack rates.
Transmission generations. Case exposure histories, observed case intervals and the absence of other potential exposure sources all support the hypothesis that at least seven discrete virus generations (six serial transmissions) occurred during this outbreak. This constitutes longest chain of human-to-human transmission of monkeypox virus yet documented. Why this chain was apparently truncated at six generations remains undetermined, but infection control recommendations made by the Ministry of Health coincident with the timing of symptom onset of the final patient (case 6) may have influenced this outcome.
A previous report from a large outbreak of monkeypox that occurred in the Katako-Kombe health zone of the Democratic Republic of Congo in 1996 alludes to a cascade of transmission that affected eight members of a single clan, but the architecture of this cluster was not described. Additionally, case identification during that outbreak was complicated by concurrent transmission of varicella virus (the agent of chickenpox) in affected communities.7,18
The case intervals range from 8 to 12 days, with a median of 10 (mean = 9.9, SD = 1.5, n = 7). The approximate elapsed time interval from the onset of illness of the first to the final case is 69 days, which in within the range of biologic plausibility for monkeypox.
Case characteristics.
There were 11 individuals in this outbreak who were classified as confirmed or probable cases of monkeypox (Appendix 1
). Eight of these 11 cases (73%) were male, and all were < 8 years (median = 8 years of age, n = 9). None had been vaccinated against smallpox (Table 1
).
Clinical characteristics of cases.
All but three of the 11 cases in this outbreak were hospitalized. Among the nine cases for whom information was available, the progression of the illness was similar, with a 23-day febrile prodrome followed by skin eruption (Figure 3A
). Rash burden tended to be higher in younger children, but the association between rash intensity and age was not significant. Disease severity was not associated with generation of transmission because the final confirmed and probable cases were not markedly less ill (nor more ill) than the initial cases.
|
Laboratory parameters.
Preservative-containing blood specimens were obtained from a subset of case patients. No blood specimens sent to CDC yielded live virus, but EDTA-whole blood from three of five patients examined (all of whom had severe rash burdens) yielded evidence of virus-specific DNA signatures (Table 2
). Two additional case-patient blood samples yielded no evidence of viral DNA.
|
Febrile rash illness not attributable to monkeypox. Three individuals 2, 7, and 21 years of age came to the Government Hospital in Impfondo with febrile rash illnesses (the two younger individuals came on July 7, 2003 and the adult came on July 19). All three were residents of Impfoundo; none had a defined epidemiologic relationship with any known human monkeypox case. All three complained of (current or prior) fever, and pruritic, vesicular-pustular rash, although none had defined febrile prodromes prior to rash development. On examination, all had lymphadenopathy and cough. In addition, the youngest patient had pronounced rhinorrhea and dyspnea. The eldest patient, whose infant daughter had experienced a similar illness days earlier, had both rhinorrhea and headache on presentation. All three patients were sent home after evaluation with diagnoses of varicella.
Laboratory tests performed on EDTA-whole blood specimens collected from all three individuals were negative for monkeypox virus by PCR and virus culture, as was a rash lesion specimen collected from the 21-year old person. Serologic specimens collected from the 2- and 7-year-old children (on days 14 and 20 post-rash onset, respectively) were also negative for orthopox virusreactive immunoglobulins. None of these individuals were considered to have had monkeypox virus infection.
| DISCUSSION |
|
|
|---|
Vaccination for smallpox anywhere from 3 to 19 years prior to exposure has been demonstrated to be up to 85% effective in protecting against infection with monkeypox virus.18 Thus, it is not unusual that health care workers were spared during this outbreak. Routine smallpox vaccinations did not cease in most regions of Africa until 1980. Therefore, individuals born before that date would likely have had an opportunity to be vaccinated. The chief of Medicine and Pediatrics at the Government Hospital and both of the health care workers whose children were case patients had a history of smallpox vaccination. This not withstanding, doctors and nurses at the Government Hospital in Impfondo had little to no access to personal protective equipment (examination gloves, gowns, masks, respirators, etc.), or supplies for disinfection or hand washing. Although todays hospital worker may retain the benefit of vaccine-derived immunologic protection, it is conceivable that health care workers will become increasingly vulnerable as more unvaccinated individuals come of age and join the professional workforce. Thus, there exists the future potential for larger and more frequent hospital-associated monkeypox outbreaks. Such occurrences could have devastating impacts on local health care infrastructure, underscoring the need to explore vaccination strategies for at risk populations. There are currently no recognized guidelines for the use of smallpox vaccines (vaccinia) for the prevention or control of monkeypox in communities with a high prevalence of human immunodeficiency virus (HIV) because of concerns over the potential for severe adverse events.
The existence of a stable zoonotic reservoir source for the virus around the hospital compound in Impfondo cannot be entirely discounted, but several observations support a hypothesis of sustained chain of human-to-human transmission. These include the clustering of successive cases within families, the uniformity of case intervals, and patient exposure histories that emphasized extensive human-to-human contact. However, this is not the first documented hospital-based outbreak of monkeypox. Human-to-human transmission of monkeypox virus among children in a hospital setting has been reported,6 but in that instance the chain of transmission was truncated at the fourth generation, and the observed case intervals were relatively long (median = 17.5 days). Here, in contrast, we hypothesize the existence of at least six serial transmissions of virus with relatively short (median = 10 days), uniform case intervals, which is suggestive of either intense exposures or highly efficient transmission.
The suggestion of efficient transmission during this outbreak is significant because monkeypox virus has often been considered to be of only nominal importance as a human pathogen, due principally to its perceived limited capacity for human-to-human spread. This notion received support from stochastic models developed by Jezek and others19 and elaborated by Fine and others,20 which simulated outcomes of monkeypox outbreaks under varied epidemiologic parameters (i.e., vaccination coverage, secondary attack rates). These models projected that even under highly permissive scenarios, assuming maximum estimates for secondary attack rates (~4% aggregated) and 0% vaccine-derived immunity within the population, less than 10% of the predicted virus introductions would lead to transmission chains greater than five generations, and ultimately none would spur community-wide epidemics.
Using these models as a guide, the existence of the extended chain of monkeypox transmission described in this report (in theory a rare event) would imply that there is a substantial, unappreciated background incidence of monkeypox in the region. An alternative interpretation might be that these models, which accentuate the lack of monkeypox virus transmissibility among humans, no longer provide an accurate representation of the epidemic potential of the virus. This may be due to changes within human or zoonotic populations (e.g., the spread of HIV, altered access to health care facilities, altered population age structure of the population, ecologic disturbance, etc.)
More recently, Antia and others21 have used epidemiologic models simulating outcomes of zoonotic virus introductions into human communities to suggest that when the perceived basic reproductive rate (R0) of a virus in human populations is too low to suggest epidemic potential (R0 < 1), even minor, incremental increases in the contact frequency, or in the efficiency of person-to-person transmission (which could be behaviorally or ecologically driven, or a consequence of genetic changes in the virus), can substantially enhance opportunities for selection of more highly adapted mutants. Stated simply, more introductions and longer, more complex transmission chains can increase the probability for emergence of human-adapted viruses capable of efficient spread. This outbreak suggests the potential for both.
This outbreak was ultimately extinguished after six serial transmissions, but both the short case intervals and the extended chain of transmission seen in this outbreak serve to reinforce the idea that the potential for monkeypox virus to emerge as a significant human pathogen, may indeed be greater than previously appreciated. This outbreak occurred in a remote, underserved part of Africa, in all respects a prime location for disease emergence. That the origin of this outbreak was not definitively identified, and may have been associated with ongoing transmission in two nearby towns, argues for increased efforts aimed at disease surveillance and definitive case identification to better understand the overall burden of disease and to identify sources for virus introduction into communities. Additionally, the potential vulnerability of health care workers (and their children) in Impfondo and other monkeypox-endemic areas should stimulate consideration of new strategies for vaccination, possibly involving replication deficient, or less reactogenic vaccines such as modified vaccinia Ankara,22 which have the potential to circumvent problems associated with risk factors (including HIV) for adverse events from the current smallpox vaccine.
Received December 30, 2004. Accepted for publication February 22, 2005.
We thank the World Health Organization Regional Office for Africa in Brazzaville, the U.S. Department of State, and the Ministry of Health and Populations of the Republic of Congo for their assistance during this outbreak. For more information on monkeypox, please visit www.cdc.gov/ncidod/monkeypox.
These authors contributed equally to this work. ![]()
* Address correspondence to Dr. Mary G. Reynolds, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333. E-mail: nzr6{at}cdc.gov ![]()
Note: The case definition for human monkeypox in the Republic of Congo appears online at www.ajtmh.org.
Authors addresses: Lynne A. Learned, School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY 14214-3013. Mary G. Reynolds, Yu Li, Victoria A. Olson, Kevin Karem, Linda L. Stempora, Zach H. Braden, Richard Kline, Anna Likos, and Inger K. Damon, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop G-18, Atlanta, GA 30333, Telephone: 404-639-2878, Fax: 404-639-3111, E-mail: nzr6{at}cdc.gov. Demole Wassa Wassa, Ministry of Health and Populations, Impfondo, Republic of Congo. François Libama, Henri Moudzeo, Jean Daniel Bolanda, Paul Tarangonia, and Paul Boumandoki, Ministry of Health and Populations, Brazzaville, Republic of Congo. Pierre Formenty, Alert and Response Operations Office, World Health Organization, Geneva, Switzerland. Joseph M. Harvey, Global Outreach Mission, Pioneer Christian Hospital, Imp-fondo, Republic of Congo.
| REFERENCES |
|
|
|---|
This article has been cited by other articles:
![]() |
V. S. Meyer, W. Kastenmuller, G. Gasteiger, M. Franz-Wachtel, T. Lamkemeyer, H.-G. Rammensee, S. Stevanovic, D. Sigurdardottir, and I. Drexler Long-Term Immunity against Actual Poxviral HLA Ligands as Identified by Differential Stable Isotope Labeling J. Immunol., November 1, 2008; 181(9): 6371 - 6383. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Lederman, M. G. Reynolds, K. Karem, Z. Braden, L. A. Learned-Orozco, D. Wassa-Wassa, O. Moundeli, C. Hughes, J. Harvey, R. Regnery, et al. Prevalence of Antibodies against Orthopoxviruses among Residents of Likouala Region, Republic of Congo: Evidence for Monkeypox Virus Exposure Am J Trop Med Hyg, December 1, 2007; 77(6): 1150 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
Monkeypox: Multiple Generations of Spread Among Humans in Africa Journal Watch Infectious Diseases, September 9, 2005; 2005(909): 4 - 4. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |